Fluoxetine Versus Bupropion in Suicide Attempters With Major Depressive Disorder

氟西汀与安非他酮治疗患有重度抑郁症的自杀未遂者

• 批准号: 7176838
• 负责人: Michael F Grunebaum
• 金额: $ 17.69万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-06 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7176838
• 关键词: Admission activity; Aggressive behavior; Alleles; American; Antidepressive Agents; Area; Attention; Award; Bupropion; Cause of Death; Clinical; Clinical Trials; Clinical Trials Design; Consultations; Depressed mood; Depression and Suicide; Development; Diagnostic and Statistical Manual; Disease susceptibility; Double-Blind Method; Event; Feeling suicidal; Fluoxetine; Frequencies; Genes; Genetic; Genetic Polymorphism; Genetic Variation; Genotype; Goals; Hospitals; Impulsivity; K-Series Research Career Programs; Knowledge; Major Depressive Disorder; Measures; Mediating; Mental Depression; Mental disorders; Mentors; Mentorship; Methaqualone; Methods; Mood Disorders; Moods; Neurobiology; Neuropsychological Tests; Patients; Persons; Pharmaceutical Preparations; Pharmacogenetics; Principal Investigator; Process; Purpose; Randomized; Recording of previous events; Research; Research Personnel; Research Project Grants; Risk; Risk Factors; Sampling; Serotonin Agents; Severities; Statistical Methods; Suicide; Suicide attempt; Suicide prevention; Therapeutic Effect; Training; Variant; Work; career; disability; experience; genetic epidemiology; improved; knowledge base; male; neuropsychological; patient oriented; prevent; programs; promoter; research and development; response; sex; single episode major depressive disorder; skills; suicidal; suicidal act; suicidal behavior; suicidal risk; trial comparing

DESCRIPTION (provided by applicant): Major depressive disorder (MOD) is a common and serious psychiatric illness. It is among the leading causes of disability and is the psychiatric disorder most frequently associated with suicide. Yet the treatment of MOD with antidepressant medication remains largely a trial-and-error process and little empirical evidence exists to guide treatment when suicide prevention is a priority. The purpose of this patient-oriented K-award is to develop and execute a program of research that will investigate clinical, neuropsychological and genetic predictors of response to different types of antidepressant medications in a high-risk sample of persons with MOD and a history of suicide attempt. Changes in clinical and neuropsychological components of depression and the diathesis for suicide will be compared during treatment with a serotonergic versus a non- serotonergic antidepressant. We will also determine whether functional polymorphisms in genes related to depression or the diathesis for suicide predict therapeutic effects of these antidepressants on mood or components of the diathesis for suicide. The principal investigator will carry out this program of research career development under the strong mentorship of Dr. J. John Mann (for training in the clinical neurobiology of depression and suicide). Active consultation and additional mentorship will come from Dr. A. John Rush (for training in antidepressant clinical trial design and execution), Dr. Bruce G. Pollock (for training in antidepressant pharmacogenetics), Dr. Joseph D. Terwilliger (for training in genetic epidemiology), Dr. John Keilp (for training in use of neuropsychological tests) and from Dr. Eva Petkova (for training in statistical analytic methods). This patient-oriented career development award will provide the principal investigator with the further experience and skills necessary to integrate clinical and scientific expertise in the field of depression and suicide clinical trials research. The long-term goal of this award is for the candidate to become an expert and independent clinical researcher on the treatment of depression with a special focus on suicide prevention.

描述(申请人提供)：严重抑郁障碍(MOD)是一种常见和严重的精神疾病。它是导致残疾的主要原因之一，也是最常与自杀有关的精神障碍。然而，使用抗抑郁药物治疗MOD在很大程度上仍然是一个反复试验的过程，当自杀预防被优先考虑时，几乎没有经验证据来指导治疗。这项以患者为导向的K奖的目的是开发和执行一项研究计划，该计划将在有自杀未遂病史的MOD高危患者样本中调查不同类型抗抑郁药物反应的临床、神经心理学和遗传预测因素。在使用5-羟色胺能和非5-羟色胺能抗抑郁药治疗期间，将比较抑郁症的临床和神经心理成分的变化以及自杀的素质。我们还将确定与抑郁或自杀素质相关的基因的功能多态性是否可以预测这些抗抑郁药物对情绪或自杀素质成分的治疗效果。首席研究员将在J.John Mann博士(抑郁症和自杀的临床神经生物学培训)的大力指导下开展这一研究职业发展计划。积极的咨询和额外的指导将来自A.John Rush博士(抗抑郁药临床试验设计和执行方面的培训)、Bruce G.Pollock博士(抗抑郁药遗传学方面的培训)、Joseph D.Terweiger博士(遗传流行病学方面的培训)、John Keilp博士(神经心理测试使用方面的培训)和Eva Petkova博士(统计分析方法方面的培训)。这一以患者为导向的职业发展奖将为首席研究员提供必要的进一步经验和技能，以整合抑郁症和自杀临床试验研究领域的临床和科学专业知识。该奖项的长期目标是让候选人成为抑郁症治疗方面的专家和独立的临床研究人员，特别关注自杀预防。